Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its partner Vetbiolix, a veterinary biotechnology company based in France, announced publication of Landmark Proof-of-Concept Clinical Study Results for VBX-1000, previously known as MIV-701, in Canine Periodontitis in Frontiers in Veterinary Science, a leading peer-reviewed scientific journal.

The publication demonstrates that VBX-1000 (MIV-701), the first specific cathepsin-K inhibitor for the treatment of periodontal disease in dogs, effectively reaches its molecular target, inhibits cathepsin-K activity, and promotes alveolar bone healing and regression of periodontitis. These results highlight the therapeutic potential of VBX-1000 (MIV-701) as a safe approach for treating mild to moderate periodontitis in dogs and support its continued development in this indication. The article is in open-access at https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1656782/full

- “This publication in an internationally recognized veterinary science journal with a peer-review process, validates VBX-1000 as the first veterinary drug candidate to promote alveolar bone healing in dogs with mild to moderate periodontitis. We believe that VBX1000 (MIV-701) has the potential to become a true groundbreaking disease modifier and VBX1000 (MIV-701) is now advancing through the development process to obtain regulatory approval. A double-blind, randomized, dose-ranging, placebo-controlled clinical trial in dogs suffering from periodontitis is being launched to confirm the potential of VBX1000 in this indication” says Matthieu Dubruque, Founder and Managing Director of Vetbiolix.

- “Partnering and collaborations are important parts of Medivir’s business model. MIV-701 is another example of the company’s ability and track-record in out-licensing to generate additional value for shareholders. It is highly encouraging to see the continued progress of the VBX-1000 (MIV-701) program made by the Vetbiolix team and we look forward to seeing the results of the randomized, placebo-controlled study now being launched to confirm the clinical benefit. If positive, it would provide a significant, positive value inflection for the VBX-1000 (MIV-701) program” says Jens Lindberg, Chief Executive Officer at Medivir.

As part of the agreement with Vetbiolix, Medivir is entitled to minor development and regulatory milestone payments with value upside potential coming from future royalty payments on net sales and share of partnering payments received by Vetbiolix, in case of future partnering transactions with VBX-1000.

For additional information, please contact;
Magnus Christensen
Chief Financial Officer
Medivir AB
Telephone: +46 8 5468 3100
Email: Magnus.Christensen@medivir.com

About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list. www.medivir.com. 

About Vetbiolix
Vetbiolix develops first-in-class clinical-stage drug candidates (oral small molecules) for the treatment of canine and feline periodontitis, osteoarthritis and intestinal motility disorders. Vetbiolix has built a unique pipeline of innovative drug candidates licensed (exclusive and worldwide license) from Human Health Biotech companies worldwide that will address unmet veterinary medical needs. Vetbiolix focuses exclusively on the clinical developments of its drug candidates and invests in (i) proof-of-concept clinical studies, (ii) CMC-Pharmaceutical developments, and (iii) regulatory clinical pilot and pivotal studies. The company's revenue generation will be based on sublicensing and/or co-development agreements with the veterinary pharmaceutical industry. www.vetbiolix.com.

Attachments
Press Release (PDF)

Läs mer på MFN